COX-2 specific inhibitors: Are NSAIDs and the stomach become reconcilied?;Inhibiteurs sélectifs de COX-2 : AINS et estomac enfin réconciliés?

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 4 SUPPL., 2001, Pages

  Bannwarth, B ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CONFERENCE PAPER; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; RISK FACTOR; STOMACH; ULCEROGENESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DUODENAL ULCER; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; STOMACH ULCER; SULFONAMIDES; SULFONES;

EID: 0034924261     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Treating acute pain in hospital
2. Is the WHO analgesic ladder for cancer pain management appropriate for rheumatology patients?
3. Towards a GI safer antiinflammatory therapy
4. ASHP therapeutic position statement on the safe use of oral nonprescription analgesics
5. La prescription des anti-inflammatoires non stéroïdiens
6. Epidemiology of NSAID induced gastrointestinal complications
7. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definition and epidemiology
8. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
9. Peptic ulcer bleeding : Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
10. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations
11. Nouveaux anti-inflammatoires non stéroïdiens: Donneurs de NO et inhibiteurs sélectifs de COX-2
12. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin - Like drugs
13. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
14. Inhibiteurs spécifiques de la cyclo-oxygénase 2: Une révolution?
15. Basic biology and clinical application of specific cyclo-oxygenase-2 inhibitors
16. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
17. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
18. Decisions loom on selective COX-2 inhibitors
19. Rofecoxib
20. Rofecoxib and celecoxib. A comparison of 2 specific COX-2 inhibitors: A randomized, placebo and active - Comparator controlled clinical trial
21. Update on clinical development with celecoxib, a new specific COX-2 inhibitor: What can we expect?
22. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial
23. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
24. Do cyclooxygenase 2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity?
25. Influence of H. pylori infection and/or low dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs
26. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
27. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
28. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double blind, placebo-controlled trial
29. Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?
30. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal events in osteoarthritis and rheumatoid arthritis as compared to NSAIDs
31. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
32. The number needed to be treated as a valuable parameter in interpreting clinical findings
33. Confidence intervals for the number needed to treat
34. Early experience with selective COX-2 inhibitors: Safety profile over 340,000 patient years of use
35. FDA handling of ADR reports needs improvement
36. Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs)
37. COX-I sparing NSAIDs-Is the enthusiasm justified?
38. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
39. COX-2 inhibitors
40. Selective COX-2 inhibitors and human inflammatory bowel disease
41. Retentissements et effets indésirables des anti-inflammatoires non stéroïdiens sur l'intestin. Effets des AINS sur l'intestin grêle et le côlon
42. Complications intestinales des antiinflammatoires non stéroïdiens
43. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy
44. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
45. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclo-oxygenase-2 gene in human vascular endothelium
46. Cardiovascular safety profile of rofecoxib in controlled clinical trials
47. Towards a better aspirin
48. AINS inhibiteurs sélectifs de COX-2 : Espoirs et incertitudes